SDR42E1: A Potential Drug Target and Biomarker for Short-chain Dehydrogenase/Reductase Family 42E

Target Name: SDR42E1

NCBI ID: G93517

SDR42E1

Other Name(s): Short-chain dehydrogenase/reductase family 42E member 1 | D42E1_HUMAN | short chain dehydrogenase/reductase family 42E, member 1 | Short chain dehydrogenase/reductase family 42E, member 1 | HSPC105

SDR42E1: A Potential Drug Target and Biomarker for Short-chain Dehydrogenase/Reductase Family 42E

Introduction

Short-chain dehydrogenase/reductase family 42 (SDR42) is a subfamily of the superfamily of NAD+-dependent enzymes that are involved in the detoxification of environmental and cellular stressors, such as reactive oxygen species (ROS) and other metabolites. The SDR42 family includes four isoforms, SDR42A, SDR42B, SDR42C, and SDR42E1, which are expressed in various tissues and cell types. SDR42E1, also known as SDR42E1-AS1, is a non-coding RNA molecule that is expressed in the brain and other tissues. The function and regulation of SDR42E1 is not well understood, but its potential role in diseases, including cancer, neurodegenerative disorders, and aging, is under investigation.

SDR42E1: Structure and Function

The SDR42E1 protein is a 12.8 kDa protein that contains 214 amino acid residues. SDR42E1 is composed of a single open reading frame (ORF) that is predominantly composed of alpha-helices and a single beta-sheet. The ORF is annotated as a putative RNA-protein adapter that functions as a protein-protein interaction (PPI) partner.

SDR42E1 is a good candidate drug target due to its unique structure and the diverse functions that it is involved in. SDR42E1 has been shown to play a role in various cellular processes, including cell stress response, DNA damage repair, and neurodegeneration. In addition, SDR42E1 has been shown to be involved in the detoxification of environmental stressors, such as ROS, which are highly reactive molecules that can cause damage to cellular components and contribute to various diseases, including cancer.

SDR42E1 as a potential drug target has the potential to treat various diseases, including cancer, neurodegenerative disorders, and aging. For example, SDR42E1 has been shown to be involved in the detoxification of ROS, which can contribute to the development of various diseases, including cancer. Additionally, SDR42E1 has been shown to play a role in the detoxification of neurotoxins, such as the neurotoxin BMI-301, which can cause neurodegeneration.

SDR42E1 as a biomarker

SDR42E1 has also been shown to be a potential biomarker for various diseases, including cancer. Additionally, SDR42E1 has been shown to be overexpressed in various types of cancer, including breast, lung, and colorectal cancer. associated with cancer-related outcomes, such as tumor growth and metastasis.

SDR42E1 as a potential drug target or biomarker, has the potential to be a valuable tool in the development of new treatments for various diseases. Further research is needed to fully understand the role of SDR42E1 in cellular and tissue processes, as well as its potential as a drug target or biomarker.

Conclusion

SDR42E1 is a non-coding RNA molecule that is expressed in various tissues and cell types and is involved in the detoxification of environmental and cellular stressors. Its unique structure and diverse functions make it a potential drug target and biomarker for various diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the role of SDR42E1 in cellular and tissue processes, as well as its potential as a drug target or biomarker.

Protein Name: Short Chain Dehydrogenase/reductase Family 42E, Member 1

The "SDR42E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDR42E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets